Table 1.
Demographic, Clinical, and Transplant Characteristics
| N (%) | |
|---|---|
| Number of patients | 457 |
| Patient age, years (median, range) | 65.9 (60-78.7) |
| Patient age, ≥70 | 77 (17) |
| Female Gender | 177 (39) |
| Disease Indication | |
| Myeloid malignancies | 315 (69) |
| Lymphoid malignancies | 142 (31) |
| Karnofsky Performance Score (KPS) | |
| ≥90 | 242 (53) |
| <90 | 211 (47) |
| Missing information | 4 |
| Hematopoietic Cell Transplant-Comorbidity/Age Index (HCT-CI/age) | |
| <5 | 307 (67) |
| ≥5 | 150 (33) |
| Disease Risk Index (DRI) | |
| Low/Intermediate | 327 (72) |
| High/Very high | 130 (28) |
| Donor HLA-type | |
| Match related donor | 127 (28) |
| Match unrelated donor | 247 (54) |
| Mismatch (≤7/8) unrelated donor | 58 (13) |
| Haploidentical donor | 25 (5) |
| Conditioning Intensity | |
| Myeloablative | 274 (60) |
| NMA/RIC | 183 (40) |
| Patient CMV Status | |
| Negative | 190 (42) |
| Positive | 267 (58) |
| Graft Source | |
| Bone marrow | 55 (12) |
| Peripheral blood | 402 (88) |
| Follow-up of survivors, months (median, range) | 37 (2 – 102) |
Abbreviations: HLA, Human Leukocyte Antigen; NMA/RIC, Non-myeloablative/Reduced intensity conditioning; CMV, Cytomegalovirus.